Diffusion Pharmaceuticals Takes Aim At Brain Cancer: CEO David Kalergis
April 05, 2016 at 10:52 AM EDT
David Kalergis, CEO of Diffusion Pharmaceutical lays out the plan for pivotal development of treatment for primary brain cancer, which could drive the company's market cap to valuations that would bring huge upside to investors if successful.